- Home
- SLN vs AZ Comparison
SLN vs AZ Comparison
Compare SLN & AZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SLN
- AZ
- Stock Information
- Founded
- SLN 1994
- AZ 2018
- Country
- SLN United Kingdom
- AZ Canada
- Employees
- SLN N/A
- AZ N/A
- Industry
- SLN Biotechnology: Pharmaceutical Preparations
- AZ Industrial Machinery/Components
- Sector
- SLN Health Care
- AZ Industrials
- Exchange
- SLN Nasdaq
- AZ Nasdaq
- Market Cap
- SLN 299.4M
- AZ 339.2M
- IPO Year
- SLN N/A
- AZ N/A
- Fundamental
- Price
- SLN $4.81
- AZ $8.87
- Analyst Decision
- SLN Buy
- AZ Strong Buy
- Analyst Count
- SLN 5
- AZ 1
- Target Price
- SLN $32.60
- AZ $20.00
- AVG Volume (30 Days)
- SLN 60.5K
- AZ 166.5K
- Earning Date
- SLN 08-07-2025
- AZ 08-13-2025
- Dividend Yield
- SLN N/A
- AZ N/A
- EPS Growth
- SLN N/A
- AZ N/A
- EPS
- SLN N/A
- AZ N/A
- Revenue
- SLN $27,169,000.00
- AZ $7,489,000.00
- Revenue This Year
- SLN N/A
- AZ $1,343,857.60
- Revenue Next Year
- SLN N/A
- AZ N/A
- P/E Ratio
- SLN N/A
- AZ N/A
- Revenue Growth
- SLN 22.28
- AZ 19.04
- 52 Week Low
- SLN $1.97
- AZ $1.38
- 52 Week High
- SLN $20.48
- AZ $12.36
- Technical
- Relative Strength Index (RSI)
- SLN 34.88
- AZ 40.24
- Support Level
- SLN $4.91
- AZ $8.54
- Resistance Level
- SLN $5.34
- AZ $9.58
- Average True Range (ATR)
- SLN 0.48
- AZ 0.50
- MACD
- SLN -0.05
- AZ -0.04
- Stochastic Oscillator
- SLN 0.71
- AZ 20.68
About SLN Silence Therapeutics Plc American Depository Share
Silence Therapeutics PLC is a biotechnology company focused on discovering and developing novel molecules incorporating short-interfering ribonucleic acid or siRNA. Using its mRNAi GOLD platform, the company has generated siRNA product candidates both for internal development pipeline as well as for out-licensed programs with third-party collaborators. Its wholly owned pipeline is focused on three therapeutic areas: cardiovascular disease, hematology, and rare diseases. The different product candidates in its pipeline are Divesiran (SLN124), a siRNA product candidate that has the potential to treat several hematological disorders; Zerlasiran (SLN360), being developed as a potential treatment to reduce cardiovascular issues; SLN-312; SLN-548; and multiple other programs.
About AZ A2Z Smart Technologies Corp.
A2Z Cust2Mate Solutions Corp is engaged in creating shopping carts. With the help of a user-friendly smart algorithm, touch screen, and other technologies, the company streamlines the retail shopping experience by scanning purchased products and enabling in-cart payment so that customers can simply pick & go, and bypass long cashier checkout lines.